Richard S Lindahl insider trades: Emergent BioSolutions (EBS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Richard reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 15, 2021 | EBS | ↑ Buy | 3,000 | $37.46 | $112K | Direct | Nov 15, 2021 (0d) |
| Aug 1, 2014 | CEB | ↓ Sell | 15,000 | $61.76 | $926K | Direct | Aug 1, 2014 (0d) |
| Nov 20, 2012 | EXBD | ↑ Buy | 1,000 | $41.50 | $42K | Direct | Nov 20, 2012 (0d) |
| Aug 19, 2005 | S | ↓ Sell | 49,374 | $26.12 | $1.3M | Direct | Aug 19, 2005 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other EBS insiders
Open-market trades in the last 12 months
About Richard S Lindahl's insider trades
Richard S Lindahl is EVP, Chief Financial Officer at Emergent BioSolutions (EBS). Since Aug 19, 2005, Richard has reported 2 open-market purchases worth $154K and 2 sales worth $2.2M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include shares withheld for taxes (39 filings), grants and awards (34 filings), option exercises (21 filings), shares returned to the company (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EBS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.